Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Inc
With
Astellas Pharma US, Inc.
A phase II, multicenter, open-label study in subjects with unresectable Stage III or metastatic (Stage IV) Melanoma to evaluate the efficacy and safety of YM155
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed unresectable stage III or IV malignant melanoma
Life expectancy \>12 weeks
You may not be if
History of other malignancy in the last 5 years
Major surgery within the past 21 days
Clareo Health | A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma
